Key points are not available for this paper at this time.
Moderate-to-severe atopic dermatitis (AD) can be difficult to manage in paediatric patients, with few licensed treatments in this age group. Dupilumab is approved for AD in children older than 6 months.
Iznardo et al. (Fri,) studied this question.